Analysis Of Income And Expense [Abstract]

Zealand Pharma - Filing #1417063

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
292,567,000 DKK
353,314,000 DKK
41,333,000 DKK
Material income and expense [abstract]
Royalty expense
10,970,000 DKK
0 DKK
415,000 DKK
Research and development expense
588,453,000 DKK
604,081,000 DKK
561,423,000 DKK
Operating expense
1,224,709,000 DKK
1,092,107,000 DKK
629,304,000 DKK
Sales and marketing expense
375,269,000 DKK
285,256,000 DKK
0 DKK
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
5,178,000 DKK
8,977,000 DKK
0 DKK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
1,012,972,000 DKK
837,752,000 DKK
571,541,000 DKK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
1,012,972,000 DKK
837,752,000 DKK
571,541,000 DKK

Talk to a Data Expert

Have a question? We'll get back to you promptly.